Treatment outcome and clinical characteristics of HER2 mutated advanced non‐small cell lung cancer patients in China-Reference-Cited by-同舟云学术

Treatment outcome and clinical characteristics of HER2 mutated advanced non‐small cell lung cancer patients in China

Published:2020-03 Issue:3 Volume:11 Page:679-685
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Xu Fei¹^ORCID,Yang Guangjian¹,Xu Haiyan²^ORCID,Yang Lu¹^ORCID,Qiu Weini³,Wang Yan¹^ORCID

Affiliation:

1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical College Beijing China

2. Department of Comprehensive OncologyNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

3. Haalthy Beijing China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13317

Reference30 articles.

1. Cancer statistics, 2019

2. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

3. Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer

4. Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

5. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spotlight on the treatment of non‐small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives;International Journal of Cancer;2024-07-03

2. A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations;Cancer Medicine;2024-06

3. HER2-Mutant Advanced and/or Metastatic Non–Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes;Clinical Lung Cancer;2024-06

4. Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion;Current Oncology;2023-11-14

5. Immunotherapy as a later-line option for HER2-altered advanced non-small-cell lung cancer: taxane might be a favorable partner;Future Oncology;2023-11-01